About the Company
selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $SELB News
Buy Rating Affirmed for Cartesian Therapeutics: Neutral Impact of Xork Termination and High Hopes for Descartes-08 Trial
Analyst Mitchell Kapoor of H.C. Wainwright reiterated a Buy rating on Cartesian Therapeutics (RNAC – Research Report), with a price ...
Astellas Backs Out of Potential $340M Licensing Deal with Cartesian
After forging a partnership last year, Astellas is ending the pact with Cartesian Therapeutics and stopping the development ...
New Suit - Securities
Cartesian Therapeutics f/k/a Selecta Biosciences and members of the company's board were hit with a stockholder action on Feb. 21 in New York Southern District Court centered on the company's ...
Selecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressants
Enhance gene expression and reduce immune responses with Selecta Biosciences' patented method using viral vectors and nanocarriers attached to immunosuppressants. Learn more about this innovative ...
Biotech moving HQ outside of Montgomery County following merger
The move follows Cartesian’s November merger with Selecta Biosciences Inc., a public company based in Watertown, ...
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Topline data from Phase 2b study of Descartes-08,the Company’s potential first-in-class mRNA CAR-T cell therapy, in myasthenia gravis (MG) ...
Which Is a Better Investment, Apellis Pharmaceuticals Inc or Avidity Biosciences Inc Stock?
Learn more about whether Apellis Pharmaceuticals Inc or Avidity Biosciences Inc is a better investment based on AAII's A+ ...
Assembly Biosciences Inc ASMB
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Aptose Biosciences Inc APTO
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Cartesian Therapeutics Inc (RNAC)
WATERTOWN - Selecta Biosciences (NASDAQ:SELB), a biotech company based in Watertown, Massachusetts, announced today its reverse merger with Cartesian Therapeutics. The merger ...
DJ Target - 1Xtra's UK Touchdown Tour - Touchdown Tour Mix with Selecta KB representing Derby - BBC Sounds
1Xtra goes in the mix Selecta KB UK Touchdown Tour Derby.
Loading the latest forecasts...